Market Closed -
Oslo Bors
10:45:00 2024-05-07 EDT
|
5-day change
|
1st Jan Change
|
56.9
NOK
|
+0.71%
|
|
+2.89%
|
-15.58%
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Capitalization
1 |
1,045
|
1,963
|
2,846
|
2,769
|
2,895
|
1,542
|
1,542
|
-
|
Enterprise Value (EV)
1 |
937.8
|
1,837
|
2,562
|
2,483
|
2,639
|
1,567
|
1,286
|
1,234
|
P/E ratio
|
-28.2
x
|
61.3
x
|
-117
x
|
-89.3
x
|
-40.2
x
|
6,740
x
|
1,340
x
|
23.9
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
5.75
x
|
6.97
x
|
11.1
x
|
7.68
x
|
7.73
x
|
4.09
x
|
3.12
x
|
2.58
x
|
EV / Revenue
|
5.17
x
|
6.53
x
|
9.99
x
|
6.89
x
|
7.05
x
|
3.51
x
|
2.6
x
|
2.07
x
|
EV / EBITDA
|
-89.3
x
|
31.2
x
|
-655
x
|
136
x
|
-107
x
|
28.2
x
|
37.6
x
|
10.7
x
|
EV / FCF
|
-
|
-
|
-16.9
x
|
113
x
|
-469
x
|
35.4
x
|
172
x
|
17.3
x
|
FCF Yield
|
-
|
-
|
-5.9%
|
0.89%
|
-0.21%
|
2.82%
|
0.58%
|
5.79%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
21,764
|
21,930
|
26,702
|
26,960
|
27,106
|
27,106
|
27,106
|
-
|
Reference price
2 |
48.00
|
89.50
|
106.6
|
102.7
|
106.8
|
56.90
|
56.90
|
56.90
|
Announcement Date
|
19-02-27
|
20-02-27
|
21-03-03
|
22-02-23
|
23-02-23
|
24-02-21
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net sales
1 |
181.5
|
281.6
|
256.5
|
360.5
|
374.5
|
446.2
|
495
|
597.2
|
EBITDA
1 |
-10.5
|
58.95
|
-3.912
|
18.3
|
-24.63
|
55.49
|
34.19
|
115.3
|
EBIT
1 |
-23.7
|
42.74
|
-23.2
|
-5.826
|
-49
|
27.81
|
3.877
|
83.99
|
Operating Margin
|
-13.06%
|
15.18%
|
-9.05%
|
-1.62%
|
-13.09%
|
6.23%
|
0.78%
|
14.06%
|
Earnings before Tax (EBT)
1 |
-36.72
|
45.9
|
-33.23
|
-31.66
|
-71.13
|
9.738
|
1.377
|
81.99
|
Net income
1 |
-36.74
|
31.83
|
-22.4
|
-30.9
|
-71.86
|
0.267
|
0.9877
|
64.6
|
Net margin
|
-20.24%
|
11.31%
|
-8.73%
|
-8.57%
|
-19.19%
|
0.06%
|
0.2%
|
10.82%
|
EPS
2 |
-1.700
|
1.460
|
-0.9100
|
-1.150
|
-2.660
|
0.0100
|
0.0424
|
2.385
|
Free Cash Flow
1 |
-
|
-
|
-151.2
|
21.99
|
-5.627
|
44.25
|
7.5
|
71.5
|
FCF margin
|
-
|
-
|
-58.95%
|
6.1%
|
-1.5%
|
9.92%
|
1.52%
|
11.97%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
120.16%
|
-
|
79.74%
|
21.94%
|
62.01%
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
16,573.78%
|
759.34%
|
110.68%
|
Dividend per Share
2 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
19-02-27
|
20-02-27
|
21-03-03
|
22-02-23
|
23-02-23
|
24-02-21
|
-
|
-
|
Fiscal Period: December |
2021 Q2
|
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
90.44
|
87.4
|
94.52
|
81.6
|
100.6
|
106.8
|
94.94
|
106.2
|
144.3
|
107.5
|
115
|
114.5
|
147
|
117
|
129
|
EBITDA
1 |
5.834
|
-0.2
|
-5.469
|
-13.88
|
1.4
|
4.7
|
-16.87
|
-1.2
|
23.39
|
3.339
|
29.92
|
3
|
30
|
-
|
11
|
EBIT
1 |
-0.248
|
-6.344
|
-11.5
|
-19.88
|
-4.6
|
-1.4
|
-23.1
|
-7.7
|
16.84
|
-3.852
|
22.48
|
-5
|
23
|
-7
|
4
|
Operating Margin
|
-0.27%
|
-7.26%
|
-12.17%
|
-24.36%
|
-4.57%
|
-1.31%
|
-24.33%
|
-7.25%
|
11.67%
|
-3.58%
|
19.54%
|
-4.37%
|
15.65%
|
-5.98%
|
3.1%
|
Earnings before Tax (EBT)
1 |
-7.565
|
-11.4
|
-33.03
|
-27.26
|
-9.053
|
-6.262
|
-28.56
|
-10.1
|
11.96
|
-8.666
|
16.55
|
-5.5
|
25
|
-5
|
6
|
Net income
1 |
-10.61
|
-7.301
|
-28.15
|
-21.98
|
-18.46
|
-9.932
|
-21.48
|
-11.7
|
4.311
|
-4.788
|
12.48
|
-4.5
|
20
|
-4
|
5
|
Net margin
|
-11.74%
|
-8.35%
|
-29.78%
|
-26.94%
|
-18.35%
|
-9.3%
|
-22.63%
|
-11.02%
|
2.99%
|
-4.45%
|
10.85%
|
-3.93%
|
13.61%
|
-3.42%
|
3.88%
|
EPS
2 |
-0.4000
|
-0.2700
|
-1.050
|
-0.8200
|
-0.6800
|
-0.3700
|
-0.7900
|
-0.4300
|
0.1600
|
-0.1800
|
0.4600
|
-0.0800
|
0.7200
|
-0.1500
|
0.1700
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
21-08-11
|
21-11-17
|
22-02-23
|
22-05-11
|
22-08-10
|
22-11-02
|
23-02-23
|
23-05-10
|
23-08-09
|
23-11-08
|
24-02-21
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
---|
Net Debt
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
1 |
107
|
125
|
285
|
285
|
256
|
260
|
256
|
308
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-
|
-
|
-151
|
22
|
-5.63
|
44.3
|
7.5
|
71.5
|
ROE (net income / shareholders' equity)
|
-18.6%
|
16.5%
|
-6.25%
|
-6.11%
|
-14.9%
|
0.06%
|
-0.65%
|
14.4%
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-4.34%
|
-3.95%
|
-
|
0.04%
|
2.5%
|
10.6%
|
Assets
1 |
-
|
-
|
516.7
|
782.8
|
-
|
715.8
|
39.51
|
609.4
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
1.63
|
-
|
167
|
3.7
|
3.61
|
4.06
|
3
|
2.5
|
Capex / Sales
|
0.9%
|
-
|
65.03%
|
1.03%
|
0.96%
|
0.91%
|
0.61%
|
0.42%
|
Announcement Date
|
19-02-27
|
20-02-27
|
21-03-03
|
22-02-23
|
23-02-23
|
24-02-21
|
-
|
-
|
Last Close Price
56.9
NOK Average target price
86
NOK Spread / Average Target +51.14% Consensus |
1st Jan change
|
Capi.
|
---|
| -15.58% | 142M | | +33.43% | 700B | | +26.43% | 569B | | -5.12% | 358B | | +19.59% | 330B | | +4.89% | 287B | | +14.32% | 236B | | +5.79% | 202B | | -9.49% | 197B | | +4.26% | 161B |
Other Pharmaceuticals
|